Hematopoietic stem and progenitor cell regulation for enhanced clinical efficacy

造血干细胞和祖细胞调节以增强临床疗效

基本信息

批准号：
9752987
负责人：
HAL E. BROXMEYER
金额：
$ 91.95万
依托单位：
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-08-01 至 2021-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9752987
关键词：
Advanced Development Affect Area Basic Science Biological Process Biomedical Research Bone Marrow Diseases Cell Cycle Regulation Cell Transplantation Cell Transplants Cells Cellular biology Clinic Clinical Clinical Investigator Clinical Trials Core Facility Development Disease Elements Ensure Environment Epigenetic Process Exposure to Extramural Activities Flow Cytometry Fostering Funding Funding Agency Funding Mechanisms Gene Transfer Goals Growth Growth and Development function Health Benefit Hematology Hematopoiesis Hematopoietic Hematopoietic System Hematopoietic stem cells Hereditary Disease Homing Human In Vitro Incubators Indiana Informal Social Control Infrastructure Institutes Investigation Ionizing radiation Laboratories Microscopy Mission Modality Molecular Molecular and Cellular Biology Mus Non-Malignant Optics Productivity Publications Publishing Regulation Research Research Activity Research Personnel Resources STEM research Scientist Secure Seminal Services Signal Transduction Stem cell transplant Stem cells Technology Training Translations Transplantation United States National Institutes of Health Universities Work angiogenesis base career cell behavior clinical efficacy cost environmental enrichment for laboratory animals experience fetal functional status gene therapy genetic approach hematopoietic cell transplantation hematopoietic engraftment improved in vivo interdisciplinary approach medical schools member migration operation progenitor programs public health relevance self-renewal stem success translational study

项目摘要

DESCRIPTION (provided by applicant): The proposed Indiana University School of Medicine (IUSM) Cooperative Hematology Specialized Core Center (CHSCC) brings together 28 investigators whose research activities are focused on various aspects of nonmalignant hematology and whose work is highly dependent on one or more of the four biomedical research cores proposed in this application. The central theme of our CHSCC is the regulation of human and murine hematopoiesis at the level of hematopoietic stem (HSC) and progenitor (HPC) cells. The goal of the investigations of members of this center is to leverage different components of the hematopoietic system to improve the advancement of the clinical utility and efficacy of HSC/HPC-based therapies. We believe that in order to attain these goals, we must understand basic biological processes that affect hematopoietic stem cell behavior both in vitro and in vivo in a basic science laboratory and to eventually establish clinical trials that transfor these findings into translational efforts. The proposed CHSCC membership in this application draws from a group of well-funded investigators with a diverse but complementary experience in experimental and clinical stem cell transplantation, signaling in and regulation of HSC and HPC, developmental emergence of fetal hematopoiesis, gene transfer, interactions between HSC and the hematopoietic niche, mobilization, homing and engraftment of HSC, modulation of function of freshly isolated and ex vivo manipulated HSC, and functional status of HSC after exposure to ionizing radiation. The cores proposed in this CHSCC submission evolved from existing shared facilities and have been adapted to the current needs of this program. These include: Experimental Mouse Resources, Optical Microscopy, Angiogenesis, and Flow Cytometry cores. All cores will support the basic and translational studies that underlie the mission of the CHSCC and will facilitate development of new discoveries into human trials. The program also includes a Pilot and Feasibility Project to be funded in part through Institutional funds in order to enhanc the training of young investigators and enhance their ability to successfully compete for extramural (e.g. NIH) funding. Furthermore, to ensure continued scientific growth and progress, the proposed center has a well-developed enrichment program to advance the development of both young and established CHSCC members. Together, the CHSCC represents an important assembly of critical cores needed to promote and enhance the basic and clinical work in progress and to provide support that we believe is needed over the next five years.

描述（由应用程序提供）：拟议的印第安纳大学医学院（IUSM）合作血液学专业核心中心（CHSCC）汇集了28个研究人员，他们的研究活动侧重于非恶性血液学的各个方面，其工作高度依赖于该应用程序中提出的四个生物医学研究核心中的一项或多项。我们CHSCC的中心主题是在造血茎（HSC）和祖细胞（HPC）细胞水平上对人和鼠造血的调节。对该中心成员进行调查的目的是利用造血系统的不同组成部分来提高基于HSC/HPC疗法的临床实用性和效率的进步。我们认为，为了实现这些目标，我们必须了解在基础科学实验室中影响造血干细胞行为的基本生物学过程，并在基础科学实验室中进行体外和体内，并建立了将这些发现转化为转化工作的临床试验。 The proposed CHSCC membership in this application draws from a group of well-funded investigators with a diversity but complete experience in experimental and clinical stem cell transplantation, signaling in and regulation of HSC and HPC, developmental emergence of fetal hematopoiesis, gene transfer, interactions between HSC and the hematopoietic niche, mobilization, homing and engcraftment of HSC, modulation of function of freshly isolated and ex暴露于电离辐射后，体内操纵HSC和HSC的功能状态。此CHSCC提交中提出的核心是从现有共享设施演变而来的，并已适应了该计划的当前需求。其中包括：实验小鼠资源，光学显微镜，血管生成和流式细胞仪核。所有核心将支持CHSCC使命的基础和翻译研究，并将支持将新发现发展为人类试验。该计划还包括一个试点和可行性项目，该项目将通过机构资金部分资助，以增强对年轻调查人员的培训，并增强其成功争夺外壁外（例如NIH）资金的能力。此外，为了确保持续的科学增长和进步，该拟议中心制定了一个发达的富集计划，以推动Young和已建立的CHSCC成员的发展。 CHSCC共同代表了促进和增强正在进行的基本和临床工作所需的关键核心的重要组装，并提供了我们认为在未来五年内需要的支持。